MX2009011843A - Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible. - Google Patents

Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.

Info

Publication number
MX2009011843A
MX2009011843A MX2009011843A MX2009011843A MX2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A MX 2009011843 A MX2009011843 A MX 2009011843A
Authority
MX
Mexico
Prior art keywords
reversible
intravenous
inhibitor
acting
direct
Prior art date
Application number
MX2009011843A
Other languages
English (en)
Spanish (es)
Inventor
Anjali Pandey
Pamela B Conley
Patrick Andre
Daniel D Gretler
Athiwat Hutchaleelaha
David R Phillips
Huang Wolin
Robert M Scarborough
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2009011843A publication Critical patent/MX2009011843A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009011843A 2007-05-02 2008-05-02 Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible. MX2009011843A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
MX2009011843A true MX2009011843A (es) 2010-04-22

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011843A MX2009011843A (es) 2007-05-02 2008-05-02 Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.

Country Status (17)

Country Link
US (2) US20090048216A1 (pt-PT)
EP (1) EP2079464A2 (pt-PT)
JP (1) JP2010526101A (pt-PT)
KR (1) KR20100029746A (pt-PT)
CN (1) CN101795682A (pt-PT)
AU (1) AU2008247483A1 (pt-PT)
BR (1) BRPI0811476A2 (pt-PT)
CA (1) CA2686203A1 (pt-PT)
CO (1) CO6241104A2 (pt-PT)
EA (1) EA200901473A1 (pt-PT)
EC (1) ECSP099778A (pt-PT)
GT (1) GT200900284A (pt-PT)
IL (1) IL201834A0 (pt-PT)
MA (1) MA31663B1 (pt-PT)
MX (1) MX2009011843A (pt-PT)
TN (1) TN2009000451A1 (pt-PT)
WO (1) WO2008137753A2 (pt-PT)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
KR20090115953A (ko) * 2007-03-06 2009-11-10 노파르티스 아게 염증성 또는 알레르기성 상태의 치료에 적합한 바이시클릭 유기 화합물
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR20110115578A (ko) * 2008-12-30 2011-10-21 트롬보로직 에이피에스 장기 부전이 발달할 증가된 위험이 있는 중증 질환 환자의 확인 방법 및 이의 치료를 위한 화합물
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646827A1 (en) * 2010-12-01 2013-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
MX2019009559A (es) 2017-03-15 2019-10-15 Idorsia Pharmaceuticals Ltd Administracion subcutanea de un antagonista del receptor p2y12.
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법

Also Published As

Publication number Publication date
ECSP099778A (es) 2010-01-29
KR20100029746A (ko) 2010-03-17
WO2008137753A3 (en) 2009-02-12
MA31663B1 (fr) 2010-09-01
CA2686203A1 (en) 2008-11-13
CO6241104A2 (es) 2011-01-20
EA200901473A1 (ru) 2010-06-30
AU2008247483A1 (en) 2008-11-13
CN101795682A (zh) 2010-08-04
US20120009172A1 (en) 2012-01-12
IL201834A0 (en) 2010-06-16
US20090048216A1 (en) 2009-02-19
JP2010526101A (ja) 2010-07-29
TN2009000451A1 (en) 2011-03-31
GT200900284A (es) 2012-01-31
BRPI0811476A2 (pt) 2014-11-04
WO2008137753A2 (en) 2008-11-13
EP2079464A2 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
MX2009011843A (es) Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.
HK1160779A1 (en) Cdk inhibitor for the treatment of mesothelioma
ECSP099376A (es) Inhibidores de la actividad de la akt
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
IL211825A (en) Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention
HRP20110451T1 (hr) Upotreba izotiocijanata kao sredstva protiv mieloma
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
ECSP077980A (es) Inhibidores de la actividad akt
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MY162146A (en) Pharmaceutical composition
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
EP2137175A4 (en) NOVEL PHENANTHRENNEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME INVOLVING DISEASES
IN2012DN03428A (pt-PT)
MX2010005714A (es) Compuestos de piridina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal